INCIDENCE AND RISK FACTORS FOR POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN A MULTICENTER COHORT (EBMT 2026) - Mar 14, 2026 - Abstract #A122; Pres time: Mar 23, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "GVHD prophylaxis consisted of PTCy plus mycophenolate mofetil and a calcineurin inhibitor, using peripheral blood or bone marrow as the graft source...Management included thrombopoietin receptor agonists (TPO-Ras) (n=21), TPO-Ras plus filgrastim and erythropoietin (n=7), filgrastim alone (n=13), or transfusional support; seven patients required second-line therapy (CD34⁺ boost n=3, change of TPO-Ras n=3, second transplant n=1)...Letermovir prophylaxis was used in 56/427 seropositive receptors... In this multicenter cohort of allo-HSCT recipients receiving PTCy-based GVHD prophylaxis, the incidence of PGF was not higher than that reported in non-PTCy platforms. Bone marrow graft source, CMV reactivation within 6 months, and donor-specific anti-HLA antibodies were the main independent risk factors for PGF. These findings support optimization of graft quality and intensified CMV monitoring and prophylaxis strategies in patients receiving PTCy."
Clinical • Post-transplantation • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Transplantation
|
|
Josefina Troccoli Moretti1; Adriana Vitriu1; Leandro Castellanos2; Mariano Berro3; Jorge Arbelbide4; Olivia Gelo1; Ana Gabriela Sturich2; Maria Marta Rivas3; Gonzalo Ferini4; Ana Lisa Basquiera2; Maximiliano Cattaneo5; Karla Oliveros6; Cecilia Sernaque7; Priscila Wernicke8; Georgina Bendek4; Martin Saslavsky5; Gustavo Kusminsky3; Martin Castro6; Silvina Palmer7; Sofia Pelayes8; Maria Cecilia Foncuberta1
|